CN116981684A - Nanoparticle and application thereof in detection of CAR positive expression rate - Google Patents
Nanoparticle and application thereof in detection of CAR positive expression rate Download PDFInfo
- Publication number
- CN116981684A CN116981684A CN202280020744.2A CN202280020744A CN116981684A CN 116981684 A CN116981684 A CN 116981684A CN 202280020744 A CN202280020744 A CN 202280020744A CN 116981684 A CN116981684 A CN 116981684A
- Authority
- CN
- China
- Prior art keywords
- protein
- acid sequence
- car
- amino acid
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 68
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 50
- 238000001514 detection method Methods 0.000 title claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 148
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 136
- 239000012634 fragment Substances 0.000 claims abstract description 68
- 239000002245 particle Substances 0.000 claims abstract description 45
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims abstract description 9
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims abstract description 9
- 101710204410 Scaffold protein Proteins 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 162
- 102000002029 Claudin Human genes 0.000 claims description 48
- 108050009302 Claudin Proteins 0.000 claims description 48
- 239000013612 plasmid Substances 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 101710177291 Gag polyprotein Proteins 0.000 claims description 28
- 101710125418 Major capsid protein Proteins 0.000 claims description 28
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 26
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 26
- 108010015780 Viral Core Proteins Proteins 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 19
- 238000002965 ELISA Methods 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 15
- 239000003550 marker Substances 0.000 claims description 15
- -1 EGFRVIII Proteins 0.000 claims description 14
- 238000000746 purification Methods 0.000 claims description 14
- 150000007523 nucleic acids Chemical group 0.000 claims description 13
- 238000001890 transfection Methods 0.000 claims description 13
- 101710085938 Matrix protein Proteins 0.000 claims description 12
- 101710127721 Membrane protein Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 101710132601 Capsid protein Proteins 0.000 claims description 9
- 102000035160 transmembrane proteins Human genes 0.000 claims description 8
- 108091005703 transmembrane proteins Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 108010086541 Human Immunodeficiency Virus gag Gene Products Proteins 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 6
- 241000711950 Filoviridae Species 0.000 claims description 6
- 102100032530 Glypican-3 Human genes 0.000 claims description 6
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 6
- 108010052285 Membrane Proteins Proteins 0.000 claims description 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 238000010276 construction Methods 0.000 claims description 6
- 238000000684 flow cytometry Methods 0.000 claims description 6
- 241000701447 unidentified baculovirus Species 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 5
- 102000018697 Membrane Proteins Human genes 0.000 claims description 5
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 5
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 102100032412 Basigin Human genes 0.000 claims description 4
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims description 4
- 108700012439 CA9 Proteins 0.000 claims description 4
- 102100038078 CD276 antigen Human genes 0.000 claims description 4
- 101710185679 CD276 antigen Proteins 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 238000008157 ELISA kit Methods 0.000 claims description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 4
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims description 4
- 108060003393 Granulin Proteins 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101000798441 Homo sapiens Basigin Proteins 0.000 claims description 4
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims description 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 4
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 4
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 4
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 4
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 4
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 4
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 4
- 241001138401 Kluyveromyces lactis Species 0.000 claims description 4
- 108060001084 Luciferase Proteins 0.000 claims description 4
- 239000005089 Luciferase Substances 0.000 claims description 4
- 102100023123 Mucin-16 Human genes 0.000 claims description 4
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 4
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 4
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims description 4
- 241000256251 Spodoptera frugiperda Species 0.000 claims description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 108040004564 crotonyl-CoA reductase activity proteins Proteins 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 229960000856 protein c Drugs 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 239000011534 wash buffer Substances 0.000 claims description 4
- 241000351920 Aspergillus nidulans Species 0.000 claims description 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 3
- 241000714266 Bovine leukemia virus Species 0.000 claims description 3
- 241001678559 COVID-19 virus Species 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 3
- 206010061598 Immunodeficiency Diseases 0.000 claims description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
- 241000235058 Komagataella pastoris Species 0.000 claims description 3
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 3
- 241000713112 Orthobunyavirus Species 0.000 claims description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 3
- 241000315672 SARS coronavirus Species 0.000 claims description 3
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 3
- 241000235015 Yarrowia lipolytica Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 230000007813 immunodeficiency Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 230000001177 retroviral effect Effects 0.000 claims description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 3
- 210000003501 vero cell Anatomy 0.000 claims description 3
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 claims description 2
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 claims description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- 241000271566 Aves Species 0.000 claims description 2
- 108091067183 BAGE family Proteins 0.000 claims description 2
- 102000039506 BAGE family Human genes 0.000 claims description 2
- 244000063299 Bacillus subtilis Species 0.000 claims description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims description 2
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- 241000244203 Caenorhabditis elegans Species 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 241000282552 Chlorocebus aethiops Species 0.000 claims description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 2
- 108700003471 Coronavirus 3C Proteases Proteins 0.000 claims description 2
- 108700002673 Coronavirus M Proteins Proteins 0.000 claims description 2
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 2
- 101150084967 EPCAM gene Proteins 0.000 claims description 2
- 108010026586 Ebola virus nucleoprotein VP40 Proteins 0.000 claims description 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 2
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 2
- 108091072337 GAGE family Proteins 0.000 claims description 2
- 102000040452 GAGE family Human genes 0.000 claims description 2
- 101710088083 Glomulin Proteins 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 102100022662 Guanylyl cyclase C Human genes 0.000 claims description 2
- 102000049982 HMGA2 Human genes 0.000 claims description 2
- 108700039143 HMGA2 Proteins 0.000 claims description 2
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 claims description 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 2
- 101150073387 Hmga2 gene Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 2
- 101100066427 Homo sapiens FCGR1A gene Proteins 0.000 claims description 2
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 claims description 2
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 claims description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 2
- 101001003132 Homo sapiens Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 2
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 2
- 101000946833 Homo sapiens T-cell surface glycoprotein CD8 beta chain Proteins 0.000 claims description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 2
- 101000915697 Machupo virus RING finger protein Z Proteins 0.000 claims description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 102100025096 Mesothelin Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 241000186359 Mycobacterium Species 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 102100035486 Nectin-4 Human genes 0.000 claims description 2
- 101710043865 Nectin-4 Proteins 0.000 claims description 2
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 2
- 101710141454 Nucleoprotein Proteins 0.000 claims description 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims description 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 2
- 102100035721 Syndecan-1 Human genes 0.000 claims description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 2
- 102100034928 T-cell surface glycoprotein CD8 beta chain Human genes 0.000 claims description 2
- 101001051488 Takifugu rubripes Neural cell adhesion molecule L1 Proteins 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 108700041558 Vesicular stomatitis virus M Proteins 0.000 claims description 2
- 241000222126 [Candida] glabrata Species 0.000 claims description 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 108010036226 antigen CYFRA21.1 Proteins 0.000 claims description 2
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 208000032343 candida glabrata infection Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 229910052707 ruthenium Inorganic materials 0.000 claims description 2
- 239000012089 stop solution Substances 0.000 claims description 2
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 claims description 2
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 claims description 2
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 101000936049 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) Outer membrane lipoprotein Blc Proteins 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 93
- 235000018102 proteins Nutrition 0.000 description 57
- 150000001413 amino acids Chemical group 0.000 description 43
- 229950007157 zolbetuximab Drugs 0.000 description 30
- 239000005090 green fluorescent protein Substances 0.000 description 25
- 239000000427 antigen Substances 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 230000027455 binding Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 229960002450 ofatumumab Drugs 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 210000003289 regulatory T cell Anatomy 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 238000012575 bio-layer interferometry Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 210000000581 natural killer T-cell Anatomy 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 230000034303 cell budding Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241001195348 Nusa Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XWNJMSJGJFSGRY-UHFFFAOYSA-N 2-(benzylamino)-3,7-dihydropurin-6-one Chemical compound N1C=2N=CNC=2C(=O)N=C1NCC1=CC=CC=C1 XWNJMSJGJFSGRY-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 241000255993 Trichoplusia ni Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- LMFAFFIRCNUJJO-UHFFFAOYSA-N 5-(4-azidophenyl)-8-iodo-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1N(C)CCC2=CC(I)=C(O)C=C2C1C1=CC=C(N=[N+]=[N-])C=C1 LMFAFFIRCNUJJO-UHFFFAOYSA-N 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 240000002112 Carya glabra Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102000017278 Glutaredoxin Human genes 0.000 description 1
- 108050005205 Glutaredoxin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091008877 NK cell receptors Proteins 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 101800001117 Ubiquitin-related Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000007195 antigen-presenting effect Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 101150106875 malE gene Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 210000002501 natural regulatory T cell Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 101150073438 nusA gene Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000013715 transcription antitermination Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
A nanoparticle comprising (i) an enveloped virus-like particle (ekp) scaffold protein and/or a functional fragment thereof, and the use thereof to detect CAR positive expression rate; and (ii) a target protein and/or a functional fragment thereof. The nanoparticle can be used to detect the positive expression rate of the CAR, and can also be used to demonstrate that the CAR can specifically bind to a target protein.
Description
The disclosure relates to the field of biotechnology, in particular to a nanoparticle and application thereof in detecting positive expression rate of CAR.
In the immune system, T cells need to kill abnormal cells by means of Antigen Presenting Cells (APCs). The APC surface has a number of MHC (major histocompatibility complex) molecules that recognize cell surface antigens and, after the APC recognizes abnormal cells, the MHC binds to the T Cell Receptor (TCR) and signals T cells. With the help of molecules such as CD3, CD4 and CD8, T cells can eventually recognize and kill abnormal cells. However, tumor cells destroy their own "fingerprints" and thus cannot be recognized by APC cells.
Chimeric antigen receptor (Chimeric Antigen Receptor, CAR) is an artificial receptor molecule made by genetic engineering techniques that confers specificity to immune effector cells (e.g., T lymphocytes) against a target epitope, thereby enhancing the T lymphocyte recognition antigen signal and activation function (Sadelain, m., r.brentjens, and i.rivere.the promise and potential pitfalls of chimeric antigen receptors.curr Opin Immunol,2009.21 (2): p.215-23.). CAR-T cells recognize specific antigens of interest in an MHC non-limiting manner and continue to activate expanded T cells. CAR-T cell therapy is essentially an Adoptive Cell Transfer (ACT), which was originally proposed as a process in which donor lymphocytes are infused into recipients during organ transplantation, which antigen mediates the development of graft rejection, and later gradually evolves into therapy for the treatment of malignant tumors (Mitchison, n.a. Studies on the immunological response to foreign tumor transplants in the mouse.i. the role of lymph node cells in conferring immunity by adoptive transfer.the Journal of experimental medicine,1955.102 (2): p.157-177.).
For CAR-T cells, the active ingredient that exerts a tumor killing effect is T cells with a positive expression rate of CAR. The packaging specification and clinical dosage of the CAR-T cell product are expressed by the number of CAR-T positive cells, and the detection of the CAR positive expression rate is an important quality control step in the CAR-T cell production process.
In the prior art, the positive expression rate of the CAR is detected mainly by Anti-Fab antibody or Protein L Protein of a light chain or a hinge region, but the method has the defect of non-specific binding, and cannot prove whether the CAR can bind to a target antigen. Therefore, the target protein has the advantage of strong specificity for detecting the positive expression rate of the CAR and is favored by the industry. However, most target proteins are difficult to prepare, and the resulting target proteins may also adversely affect the detection of the positive expression rate of the CAR. For example, due to the hydrophobic nature of the transmembrane region of the target protein, a detergent must be introduced during purification to solubilize the target protein, resulting in detergent content in the prepared target protein, and the presence of detergent can result in membrane lysis of T cells, which makes the target protein in a detergent system unusable for detection of CAR positive rate. In addition, the extracellular loop region of the target protein is used for detecting the positive expression rate of the CAR, and although the preparation difficulty of the target protein is low, the conformation of the target protein cannot be ensured to be consistent with the natural conformation due to the fact that the result of the transmembrane region is not limited, so that the defect that the CAR cannot be identified correctly exists.
To address these issues, there is a need to develop a CAR target protein that both retains the intact native conformation and is capable of specifically binding to the CAR.
Virus-like particles (VLPs), also known as Core-like particles (CLPs), are spherical or tubular protein nanostructures formed by self-assembly of viral Capsid Proteins (CPs), having a structure similar to that of a natural viral capsid, free of genome, and non-infectious. VLPs are largely classified into eblp and non-enveloped VLPs. In the case of VLPs from enveloped viruses, this process is by budding from the host cell, which results in encapsulation of the VLPs by lipid bilayer (chinese patent application CN101146522 a). U.S. patent application US20110189159A1 is based on the finding that a protein of interest can be delivered to a cell as a fused or unfused protein; in particular, VLPs made with two Gag fusions (Gag-protein of interest and Gag-protease) can deliver the protein of interest as an unfused protein to cells for treatment. The vaccine disclosed in PCT patent application WO2021022008A1 comprises VLPs, pharmaceutically acceptable excipients, carriers and/or adjuvants; wherein the VLP comprises (a) a synthetic or natural lipid bilayer, (b) an anchor molecule embedded in the lipid bilayer, and (c) an antigen bound to the anchor molecule. In recent years, eVLP has shown unique research and application value in numerous fields such as vaccine development, drug targeted delivery, biomedical imaging and sensing, tissue engineering and the like. However, studies of the rate of expression of eVLPs in CAR positives are rarely reported.
Disclosure of Invention
In order to solve the problems in the prior art, the present disclosure provides a nanoparticle and its application in detecting the positive expression rate of CAR.
Specifically, the present disclosure solves the technical problems to be solved by the present disclosure through the following technical solutions.
In one aspect of the present disclosure, there is provided a nanoparticle comprising:
(i) An enveloped virus-like particle (eVLP) scaffold protein and/or a functional fragment thereof; and
(ii) A target protein and/or a functional fragment thereof,
wherein the enveloped virus-like particle framework protein comprises a virus core protein or a functional fragment thereof, the enveloped virus-like particle framework protein or the functional fragment thereof is assembled to form enveloped virus-like particles, and the target protein and/or the functional fragment thereof is displayed on the enveloped virus-like particles to form target protein-eVLP nano particles.
In one or more embodiments, the target protein is a CAR target protein; the CAR target protein and/or functional fragment thereof is displayed on an enveloped virus-like particle to form a CAR target protein-ehlp nanoparticle.
In one or more embodiments, the virus is selected from the group consisting of retrovirus, baculovirus, filovirus, coronavirus, influenza virus, paramyxovirus, respiratory syncytial virus, arenavirus, newcastle disease virus, parainfluenza virus, bunyavirus, hepatitis c virus, hepatitis b virus.
In one or more embodiments, the retrovirus is selected from the group consisting of human immunodeficiency virus, monkey immunodeficiency virus, mouse leukemia virus, and bovine leukemia virus.
In one or more embodiments, the baculovirus is vesicular stomatitis virus.
In one or more embodiments, the filovirus is ebola virus.
In one or more embodiments, the coronavirus is selected from the group consisting of novel coronapneumoviruses (SARS-CoV-2), SARS-CoV, MERS-CoV, 229E, NL, OC43 and HKU1.
In one or more embodiments, the viral core protein is selected from the group consisting of: retrovirus Gag protein, baculovirus matrix protein M protein, filovirus core protein, coronavirus M, E and NP proteins, influenza virus M1 protein, paramyxovirus M protein, respiratory Syncytial Virus (RSV) M protein, arenavirus Z protein, newcastle disease virus M protein, parainfluenza virus M protein, bunyavirus N protein, hepatitis C virus core protein C, hepatitis b virus core protein C, and combinations thereof.
In one or more embodiments, the retroviral Gag protein is selected from the group consisting of: human immunodeficiency virus Gag protein, monkey immunodeficiency virus Gag protein, mouse leukemia virus Gag protein and bovine leukemia virus Gag protein. In one or more preferred embodiments, the retroviral Gag protein is the human immunodeficiency virus Gag protein. In one or more preferred embodiments, the human immunodeficiency virus Gag protein comprises an amino acid sequence having at least 80% or more identity to SEQ ID No.1, preferably an amino acid sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably an amino acid sequence having 98% or 99% or more identity. In one or more preferred embodiments, the amino acid sequence of the human immunodeficiency virus Gag protein is shown as SEQ ID No. 1.
In one or more embodiments, the baculovirus matrix protein M protein is a vesicular stomatitis virus M virus core protein.
In one or more embodiments, the filovirus core protein is an ebola virus VP40 virus core protein.
In one or more embodiments, the core protein of the coronavirus is selected from the group consisting of novel coronapneumovirus (SARS-CoV-2), SARS-CoV, MERS-CoV, 229E, NL, OC43 and HKU 1.
In one or more embodiments, the virus is a virus that obtains an envelope when budding from the cell membrane of a host cell.
In one or more embodiments, the CAR target protein comprises a membrane protein.
In one or more embodiments, the membrane proteins include transmembrane proteins.
In one or more embodiments, the transmembrane protein comprises a plurality of transmembrane proteins.
In one or more embodiments of the present invention, the CAR target protein is selected from the group consisting of CD20, claudin18.1, claudin18.2, CD133, GPRC5D, CCR, CCR8, BCMA, GPCR, CD147, CD19, CD123, CD138, CD22, CD30, CD33, CD38, CD70, CAIX, EGFR, EGFRVIII, FOLR1, GPC3, HER2, HGFR, anti-FMC63Ab, CLL-1, SLAMF7, CD4, CD5, CD8A & CD8B, FAP, IL13RA2, GPC3, GUCY2C, her3, PSMA, ROR1, SLAMF7, B7-H3, CD147, CEA, MUC16, nectin-4, VEGFR2, anti-RTX Ab, B7-H3, CAIX, CD7, CEA, MUC1 any of NKG2D, PSCA, uPAR, GD2, FR, PMEL, CA9, CD171/L1-CAM, IL-13Rα2, MART-1, ERBB2, ERBB3, ERBB4, NY-ESO-1, MAGE family protein, BAGE family protein, GAGE family protein, AFP, CD44v7/8, IL-11Rα, EGP-2, EGP-40, FBP, GD3, FSA, PSA, HMGA2, fetal acetylcholine receptor, leY, epCAM, mesothelin, IGFR1, CA125, CA15-3, CA19-9, CA72-4, CA242, CA50, CYFRA21-1, SCC, AFU, EBV-VCA, POA, β2-MG, PROGRP or MSLN.
In one or more embodiments, the CAR target protein comprises a multi-transmembrane protein.
In one or more embodiments, the CAR target protein is selected from any one of CD20, claudin18.2, CD133, GPRC5D, CCR, CCR8, CD19, BCMA, GPC3, CD30, CD22, EGFR, EGFRVIII, HER2, or GPCR.
In one or more embodiments, the CAR target protein is claudin18.2. In one or more preferred embodiments, the amino acid sequence of claudin18.2 comprises an amino acid sequence having at least 80% or more identity to SEQ ID No.4, preferably an amino acid sequence having more than 85%, 90%, 95%, 96%, 97%, 98%, 99% identity, more preferably an amino acid sequence having more than 98% or 99% identity. In one or more preferred embodiments, the amino acid sequence of Claudin18.2 is shown as SEQ ID No. 4.
In one or more embodiments, the CAR target protein is CD20. In one or more preferred embodiments, the amino acid sequence of CD20 comprises an amino acid sequence having at least 80% or more identity to SEQ ID No.15, preferably an amino acid sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably an amino acid sequence having 98% or 99% or more identity: more preferably, the amino acid sequence of CD20 is shown in SEQ ID No. 15.
In one or more embodiments, the CAR target protein and/or functional fragment thereof and/or the viral core protein and/or functional fragment thereof is linked to a marker.
In one or more embodiments, the N-terminus and/or C-terminus of the CAR target protein and/or functional fragment thereof and/or the N-terminus and/or C-terminus of the viral core protein and/or functional fragment thereof are linked to a tag. In one or more preferred embodiments, the C-terminus of Claudin 18.2 or the C-terminus of Gag is labeled with a label. In another preferred embodiment or embodiments, the marker is at the C-terminus of CD20 or the C-terminus of Gag.
In one or more embodiments, the label is selected from the group consisting of a detectable label, a purification label, a reporter label, and combinations thereof.
In one or more embodiments, the detectable label is selected from the group consisting of a fluorescent group, a chemiluminescent label, an electrochemiluminescent label, and combinations thereof.
In one or more embodiments, the fluorophore is selected from any one of FITC, GFP, RFP, YFP, TRITC, PE, FAM, RRX, TR, cy, cy3, cy5, ECD, PC5.5, PC7, APC-A70, APC-A75, pac-Blue, alexa488, mBBr, 5-IAF, E-118, DTAF, rhodamine Green, and KrO.
In one or more embodiments, the chemiluminescent label is an acridinium ester, isoluminol, horseradish peroxidase, or alkaline phosphatase.
In one or more embodiments, the electrochemiluminescent label is ruthenium terpyridyl or a derivative N-hydroxysuccinimide ester thereof.
In one or more embodiments, the purification Tag is selected from any of HIS-Tag, GST-Tag, MBP-Tag, nusA-Tag, FLAG-Tag, SUMO, avi-Tag, halo-Tag, and SNAP-Tag.
In one or more embodiments, the purification tag is detected by a secondary antibody.
In one or more embodiments, the reporter tag is selected from any of c-Myc, HA, or luciferase.
In one or more embodiments, the CAR target protein is displayed on the ekp, while being labeled with a marker at the C-terminus of the CAR target protein or the C-terminus of Gag.
In another aspect of the disclosure, a labeled Claudin 18.2-eVLP is provided, wherein the Claudin 18.2-eVLP is linked to a label.
In one or more embodiments, the CAR target protein-ehlp nanoparticle is a Claudin 18.2-ehlp nanoparticle, the Claudin18.2 and/or functional fragment thereof and/or the viral core protein and/or functional fragment thereof being linked to a label.
In one or more embodiments, the N-terminus and/or C-terminus of the Claudin 18.2 and/or functional fragment thereof and/or the N-terminus and/or C-terminus of the viral core protein and/or functional fragment thereof are linked to a tag.
In one or more embodiments, the enveloped virus-like particle scaffold protein is Gag protein.
In one or more embodiments, the C-terminus of the Claudin 18.2 or the C-terminus of the Gag protein is linked to a tag.
In another aspect of the disclosure, a labeled CD20-eVLP is provided, the CD20-eVLP and the label being linked.
In one or more embodiments, the CAR target protein-ehlp nanoparticle is a CD 20-ehlp nanoparticle, and the CD20 and/or functional fragment thereof and/or the viral core protein and/or functional fragment thereof is linked to a label.
In one or more embodiments, the CD20 and/or functional fragment thereof is linked to a tag at the N-terminus and/or C-terminus and/or viral core protein and/or functional fragment thereof.
In one or more embodiments, the enveloped virus-like particle scaffold protein is Gag protein.
In one or more embodiments, the C-terminus of the CD20 or the C-terminus of the Gag protein is linked to a label.
In one or more embodiments, the marker is GPF.
In one or more embodiments, the amino acid sequence of GFP comprises an amino acid sequence having at least 80% or more identity to SEQ ID No.2, preferably an amino acid sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably an amino acid sequence having 98% or more identity. In one or more preferred embodiments, the amino acid sequence of GFP is shown as SEQ ID No. 2.
In one or more embodiments, the C-terminus of the Gag protein is linked to a marker GFP, denoted Gag-GFP, and the amino acid sequence of the Gag-GFP comprises an amino acid sequence having at least 80% or more identity to SEQ ID No.3, preferably an amino acid sequence having more than 85%, 90%, 95%, 96%, 97%, 98%, 99% identity, more preferably an amino acid sequence having more than 98% or 99% identity. In one or more preferred embodiments, the Gag-GFP has the amino acid sequence shown in SEQ ID No. 3.
In one or more embodiments, the C-terminus of Claudin 18.2 is linked to a marker GFP, denoted Claudin 18.2-GFP, and the amino acid sequence of Claudin 18.2-GFP has an amino acid sequence with at least 80% or more identity to SEQ ID No.5, preferably an amino acid sequence with 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably an amino acid sequence with 98% or 99% or more identity. In one or more preferred embodiments, the amino acid sequence of Claudin 18.2-GFP is shown as SEQ ID No. 5.
In another aspect of the present disclosure, a method of preparing nanoparticles includes:
(1) Construction of recombinant plasmids:
respectively constructing a recombinant plasmid containing envelope virus-like particle (eVLP) skeleton proteins and/or functional fragment genes thereof and a recombinant plasmid containing target proteins and/or functional fragment genes thereof; or constructing a recombinant plasmid simultaneously comprising an envelope virus-like particle (eVLP) framework protein and/or a functional fragment gene thereof and a target protein and/or a functional fragment gene thereof; and
(2) Host cell transfection, protein expression and particle assembly:
transfecting the recombinant plasmid of the skeleton protein and/or the functional fragment thereof of the enveloped virus-like particle (eVLP) constructed in the step (1) and the recombinant plasmid of the target protein and/or the functional fragment thereof into a host cell, and expressing the skeleton protein and/or the functional fragment thereof of the enveloped virus-like particle and the target protein and/or the functional fragment thereof; the coated virus-like particle skeleton proteins or functional fragments thereof are assembled to form coated virus-like particles, and the target proteins and/or the functional fragments thereof are displayed on the coated virus-like particles to form target protein-eVLP nanoparticles; and, optionally,
(3) Purifying the target protein-eVLP nanoparticles.
In one or more embodiments, the coding nucleic acid sequence of the GAG comprises a nucleotide sequence having at least 80% or more identity to SEQ ID No.7, preferably a nucleotide sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably a nucleotide sequence having 98% or 99% or more identity: more preferably, the amino acid sequence of GFP is shown as SEQ ID No. 7.
In one or more embodiments, the Gag-GFP encoding nucleic acid sequence comprises a nucleotide sequence having at least 80% or more identity to SEQ ID No.8, preferably a nucleotide sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably a nucleotide sequence having 98% or 99% or more identity: more preferably, the amino acid sequence of GFP is shown as SEQ ID No. 8.
In one or more embodiments, the Claudin 18.2 encoding nucleic acid sequence comprises a nucleotide sequence having at least 80% or more identity to SEQ ID No.9, preferably a nucleotide sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably a nucleotide sequence having 98% or 99% or more identity: more preferably, the amino acid sequence of GFP is shown as SEQ ID No. 9.
In one or more embodiments, the Claudin 18.2-GFP encoding nucleic acid sequence comprises a nucleotide sequence having at least 80% or more identity to SEQ ID No.10, preferably a nucleotide sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably a nucleotide sequence having 98% or 99% or more identity: more preferably, the amino acid sequence of GFP is shown as SEQ ID No. 10.
In one or more embodiments, the coding nucleic acid sequence of CD20 comprises a nucleotide sequence having at least 80% or more identity to SEQ ID No.16, preferably a nucleotide sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably a nucleotide sequence having 98% or 99% or more identity: more preferably, the amino acid sequence of GFP is shown as SEQ ID No. 16.
In one or more embodiments, the host cell is a prokaryotic host cell or a eukaryotic host cell.
In one or more embodiments, the prokaryotic host cell is selected from bacterial cells, such as e.coli, bacillus subtilis, and mycobacterium.
In one or more embodiments, the eukaryotic host cell is selected from any one of an animal cell, a plant cell, or a fungus.
In one or more embodiments, the eukaryotic host cell is selected from any one of a yeast, insect, avian, plant, caenorhabditis elegans, and mammalian host cell.
Non-limiting examples of such insect cells are: spodoptera frugiperda (Spodoptera frugiperda) (Sf) cells, e.g., sf9, sf21, trichoplusia ni (Trichoplusia ni) cells, e.g., high Five cells, and Drosophila S2 cells.
Examples of such fungal (including yeast) host cells are Saccharomyces cerevisiae (S.cerevisiae), kluyveromyces lactis (Kluy veromyces lactis; K.lactis), candida species including Candida albicans (C.albicans) and Candida glabrata (C.glabra), aspergillus nidulans (Aspergillus nidulans), schizosaccharomyces pombe (Schizosaccharomyces pombe; S.pombe), pichia pastoris (Pichia pastoris), and yarrowia lipolytica (Yarrowia lipolytica).
Examples of such mammalian cells are COS cells, mouse L cells, LNCaP cells, chinese Hamster Ovary (CHO) cells, human Embryonic Kidney (HEK) cells (e.g., HEK293 cells), 633 cells, vero, BHK cells, african green monkey cells, CV1 cells, heLa cells, MDCK cells and Hep-2 cells.
In one or more embodiments, the host cell is selected from any one of HEK293 cells, 633 cells, vero cells, BHK cells, prokaryotic cells, yeast cells, plant cells, insect cells, and mammalian cells.
In another aspect of the disclosure, a method of detecting a positive expression rate of a CAR comprises incubating the nanoparticle or nanoparticle prepared by the method with a CAR-modified cell, and then detecting.
In one or more embodiments, the cells are washed after incubation of the cells prior to detection.
In one or more preferred embodiments, the CAR-modified cell is selected from any one of a CAR-like (HEK 293) cell, a CAR-T cell, a CAR-NK cell, a CAR-M cell, a CAR-NKT cell, a CAR-Treg cell, and a CAR- γδ T cell.
In one or more embodiments, a method of detecting a positive expression rate of a CAR comprises incubating, washing, and then detecting the labeled Claudin 18.2-ekp described above with CAR-modified cells.
Preferably, the method for detecting the positive expression rate of the CAR comprises incubating the Claudin 18.2-eVLP with the marker and the CAR-T cells, and washing for detection.
In one or more embodiments, the Claudin 18.2-eklp ensures a natural intact conformation of the CAR target protein, increasing the success rate of isolating antibodies that recognize the native membrane protein structure.
In one or more embodiments, a method of detecting a positive expression rate of a CAR comprises incubating, washing, and then detecting the aforementioned labeled CD 20-ehlp with a CAR-modified cell.
Preferably, the method for detecting the positive expression rate of the CAR comprises incubating the CD20-eVLP with the marker and the CAR-T cells, and washing for detection.
In one or more embodiments, the CD 20-ehlp ensures a natural intact conformation of the CAR target protein, increasing the success rate of isolating antibodies that recognize the native membrane protein structure.
In one or more embodiments, the incubation is at a temperature of 2 ℃ to 40 ℃, preferably 37 ℃, and/or the incubation is for a time of 15min to 2 hours, preferably 1 hour; and/or, the incubated CO 2 The concentration of (2) to 8%, preferably 5%.
In one or more embodiments, the number of washes is 1-6, preferably 3.
In one or more embodiments, the wash buffer is 0.5% -5% bsa, preferably 2% bsa.
In one or more embodiments, the assay is any one of flow cytometry assay, immunodetection, ELISA, SPR, BLI.
In one or more embodiments, the enveloped virus-like particle ehlp framework protein is a Gag protein.
In one or more embodiments, the C-terminus of the Claudin 18.2 or the C-terminus of the Gag protein is linked to a tag.
In one or more embodiments, the C-terminus of the CD20 or the C-terminus of the Gag protein is linked to a label.
In one or more embodiments, the CAR target protein is displayed on the membrane surface (fig. 1) using the ability of HIV-1 Gag to self-assemble into an ehlp. Preferably, the four transmembrane protein Claudin 18.2 is displayed on the HIV-1 Gag envelope VLP, with a marker at the C-terminus of Claudin 18.2 or the C-terminus of Gag. The rate of CAR positive expression was assessed using a Claudin 18.2-eVLP using flow cytometry detection. All Claudin 18.2-eVLPs produced by the present disclosure can be evaluated for expression of target antigen binding CARs.
In another aspect of the disclosure, a kit is provided that contains the aforementioned nanoparticle.
In one or more embodiments, the nanoparticle is a CAR target protein-ehlp nanoparticle.
In one or more embodiments, the kit contains the aforementioned labeled CAR target protein-ehlp.
In one or more embodiments, the kit contains the aforementioned labeled Claudin 18.2-eVLP.
In one or more embodiments, the kit contains the aforementioned labeled CD20-eVLP.
In one or more embodiments, the kit is an ELISA kit, SPR kit, or BLI kit.
In one or more embodiments, the ELISA kit contains the aforementioned CAR target protein-ekp, an ELISA plate, a blocking solution, a sample diluent, an enzyme conjugate, a concentrated wash solution, an enzyme substrate solution, and a stop solution.
In one or more embodiments, the SPR kit comprises the aforementioned CAR target protein-ehlp nanoparticle.
In one or more embodiments, the BLI kit comprises the aforementioned CAR target protein-ehlp nanoparticle.
The kit disclosed by the disclosure can be used for detecting the positive expression rate of the CAR, and can also prove that the CAR can specifically bind to a target protein.
In a non-limiting example, reagents for preparing and/or administering CAR target protein-ehlp can be included in the kit. The kit may further comprise reagents for assessing CAR target protein-ehlp activity in vitro and in vivo. In certain aspects, the kit may include reagents and/or devices for administration, such as an inhaler or nebulizer, and the kit may further include one or more buffers, and the like.
When the components of the kit are provided in the form of one and/or more liquid solutions, the liquid solutions are aqueous solutions, with sterile aqueous solutions being particularly preferred. Furthermore, the components of the kit may also be provided in the form of a dry powder. When the reagents and/or components are provided in dry powder form, the liquid solution may be reconstituted by the addition of a suitable solvent.
It is to be understood that within the scope of the present disclosure, the above-described technical features of the present disclosure and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. And are limited to a space, and are not described in detail herein.
FIG. 1 is a schematic diagram of the principle of HIV-Gag coated VLPs displaying multiple transmembrane target antigens.
FIG. 2 shows the result of electrophoresis of crude pure samples after sucrose density gradient centrifugation, wherein lane A is R1242 crude pure sample, lane B is RG288 crude pure sample, and lane C is RG341 crude pure sample.
Fig. 3 shows the result of electrophoresis detection of samples after Sepharose 6FF separation, wherein fig. a is R1242, fig. B is RG288, and fig. C is RG341.
FIG. 4 shows the results of R1242-210521F1 transmission electron microscopy.
FIG. 5 shows ELISA assay for binding activity of Claudin18.2-eVLP to its specific antibody IMAB362, wherein FIG. A is the ELISA assay for binding of RG288-210503F1 to IMAB 362; panel B shows ELISA detection results of RG341-210521F1 and IMAB362 binding.
Fig. 6 is a schematic diagram of an IMAB361 CAR-like structure.
FIG. 7 shows that Claudin18.2-eVLP of the present disclosure was used to evaluate IMAB362 CAR-like expression: wherein panel a is the evaluation of IMAB362 CAR-like expression when FITC-anti mFab was diluted 200-fold; panel B is an evaluation of IMAB362 CAR-like expression when FITC-Protein L is used at a concentration of 10 μg/mL; panel C is when Claudin-18.2 Protein,His Tag TM At a concentration of 10 μg/mL, it was evaluated for IMAB362 CAR-like expression; panel D is an evaluation of IMAB362 CAR-like expression when RG288-210503F1 was used at a concentration of 10 μg/mL; panel E is an evaluation of IMAB362 CAR-like expression when RG341-210521F1 was used at a concentration of 10. Mu.g/mL.
FIG. 8 shows that CD20-eVLP of the present disclosure was used to evaluate Ofatumumab CAR-like expression: RG344-210628F1 was evaluated for Ofatumumab CAR-like expression when used at a concentration of 20. Mu.g/mL.
The present disclosure discloses an eVLP and an application thereof in detecting a CAR positive expression rate. Those skilled in the art can refer to the disclosure herein to obtain the eVLP, to realize its applications, and it is specifically noted that all similar substitutions and modifications will be apparent to those skilled in the art, and are considered to be included in the present disclosure. While the methods and applications of the present disclosure have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that the disclosed techniques can be practiced and practiced with modification and alteration and combination of the methods and applications herein without departing from the spirit and scope of the present disclosure.
Definition of the definition
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
The term "virus-like particle" (VLP) refers to a structure that resembles a virus in at least one attribute but has been shown to be non-infectious. In general, virus-like particles lack the viral genome and are unable to replicate. In addition, virus-like particles can generally be produced in large quantities by heterologous expression and can be easily purified.
The term "enveloped VLP" or alternatively "eblp" refers to an enveloped virus-like particle formed by encapsulation of a virus-like particle by a lipid envelope derived from a host cell.
The term "CAR target protein" refers to a protein that specifically binds to a CAR.
The term "vlp scaffold protein" may be understood in the present disclosure as a protein forming the scaffold structure of an vlp, which may consist essentially of or include viral core proteins, as well as other proteins.
The term "viral core protein" refers to an envelope protein that in some cases is also capable of driving budding and release of particles from a host cell.
The term "functional fragment" corresponds to a fragment of a full-length protein having a truncated structure, but still retaining all or part of the function of the full-length protein; for example, for a core protein, its corresponding functional fragment may be understood as a fragment of a truncated core protein which still has the ability to form at least part of the capsid of the virus or drive budding and release of the particle from the host cell; for a target protein, its corresponding functional fragment can be understood as a fragment of a truncated target protein, which still has the ability to specifically bind to the CAR.
The term "chimeric antigen receptor" or alternatively "CAR" refers to a recombinant polypeptide construct comprising at least an extracellular antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain comprising a functional signaling domain derived from a stimulatory molecule.
The term "CAR-like (HEK 293)" refers to Chimeric Antigen Receptor (CAR) -modified HEK293 cells, i.e., HEK293 is edited with CAR means, displaying the CAR on the surface of HEK 293.
The term "CAR-NK" refers to Chimeric Antigen Receptor (CAR) modified NK cells, where NK cells are natural killer cells (natural killer cell), which are important immune cells of the body, involved not only in anti-tumor, anti-viral infection and immune modulation, but also in the development of hypersensitivity and autoimmune diseases in some cases, capable of recognizing target cells, killing mediators. NK cells are considered as effector cells which have the same potential to enhance the antitumor ability by CAR modification because of the advantages of specific target cell recognition mechanism, short physiological cycle, wide tumor killing ability and the like.
The term "CAR-M" refers to Chimeric Antigen Receptor (CAR) -modified macrophages (CAR macroges), i.e. human macrophages are edited by CAR means so that they can directly phagocytose a tumor.
The term "CAR-NKT" refers to Chimeric Antigen Receptor (CAR) modified NKT cells (Natural killer T cell), wherein NKT cells are a specific T cell subset with both T cell receptor TCRs and NK cell receptors on the cell surface. The CAR-NKT cells combine the original advantages of the NKT cells and the specificity of the CAR therapy, so that the tumor killing effect is better realized.
The term "CAR-Treg" refers to Chimeric Antigen Receptor (CAR) modified regulatory T cells (Tregs), where Tregs are a subset of T cells that control autoimmune reactivity in vivo, also referred to as suppressor T cells (suppressor T cells) in the early stage. Regulatory T cells can be classified into naturally occurring natural regulatory T cells (n T-regs) and induced adaptive regulatory T cells (a T-regs or i T-regs), such as Th3 and Tr1, and CD8 Treg and NKT cells, etc., and are closely related to autoimmune diseases, and abnormal expression thereof may lead to autoimmune diseases.
The term "CAR- γδ T" refers to Chimeric Antigen Receptor (CAR) modified γδ T cells, wherein γδ T cells are a class of T cells between adaptive immunity and innate immunity, accounting for 1% -5% of peripheral blood T lymphocytes, distributed primarily in mucosal and epithelial tissues. The γδ T cells recognize antigen without MHC restriction, not only can kill tumor cells in various ways, but also exert antigen-presenting effects as antigen-presenting cells (APC). The gamma delta T cells are changed into CAR-gamma delta T cells, so that specific antigens can be accurately identified, tumor cells can be killed efficiently, and the treatment of solid tumors can be challenged by utilizing the characteristics of the gamma delta T cells.
The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising a light chain variable region and at least one antibody fragment comprising a heavy chain variable region, wherein the light chain and heavy chain variable regions are linked consecutively by a short flexible polypeptide linker and are capable of being expressed as a single chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived.
The term "antigen" or "Ag" refers to a molecule that causes an immune response. The immune response may involve antibody production or activation of specific immunocompetent cells or both. The skilled artisan will appreciate that virtually any macromolecule, including all proteins or peptides, can act as an antigen. Furthermore, the antigen may be derived from recombinant or genomic DNA. The skilled artisan will appreciate that any DNA comprising a nucleotide sequence or portion of a nucleotide sequence encoding a protein that elicits an immune response, thus encodes an "antigen".
The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in single or double stranded form, as well as polymers thereof.
The term "ELISA" is short for Enzyme-linked immunosorbent assay (Enzyme-Linked Immunosorbnent Assay). The method comprises the steps of combining known antigen or antibody on the surface of a solid phase carrier, then incubating the antigen or antibody marked (coupled) by enzyme, and developing by a chromogenic substance, wherein the color development depth is in direct proportion to the content of a substance to be detected, and the substance can be observed by naked eyes. In ELISA experiments, there are three necessary reagents: known antigens or antibodies (for binding to a solid support); enzyme-labeled antibodies or antigens (markers); color developer (for color development). Four types of ELISA experiments are common: direct ELISA, indirect ELISA, sandwich ELISA, and competition ELISA.
The term "SPR" is a short term for surface plasmon resonance (Surface plasmon resonance), which uses the SPR principle to detect the interaction condition between a ligand and an analyte on a biosensing chip (biosensing chip), and is widely used as a universal detection platform in the fields of drug screening, scientific research and the like for analysis of affinity, binding specificity, concentration quantification and the like between biomolecules.
The term "BLI" is an abbreviation for biological film interference technique (Bio-Layer Interferometry) and is an experimental method for detecting interactions between biomolecules based on shift changes in interference patterns.
The term FACS is short for flow cytometry fluorescence sorting technology (Fluorescence activated Cell Sorting), and the flow cytometer operates on the principle that cells to be measured are stained with a specific fluorescent dye and then placed into a sample tube, and enter a flow chamber filled with sheath fluid under the pressure of gas. Cells are arranged in a single row under the restriction of sheath liquid and are ejected by a nozzle of a flow chamber to form a cell column which is perpendicularly intersected with an incident laser beam, and cells in the liquid column are excited by the laser to generate fluorescence. A series of optical systems (lenses, diaphragms, filters, detectors, etc.) in the instrument collect signals such as fluorescence, light scattering, light absorption or cell impedance, and a computer system collects, stores, displays and analyzes the various signals to be measured and performs statistical analysis on various indexes.
The term "HIS-Tag" consists of 6-10 histidine residues with a molecular weight of less than 0.84KD, typically inserted at the C-or N-terminus of the protein of interest. HIS-Tag is the most commonly used Tag for prokaryotic expression at present, and the Tag can be removed after the protein is purified, so that the function of the protein is not influenced. Meanwhile, the protein purification steps are simple and convenient, the purification conditions are mild, and the protein is not greatly influenced.
The term "GST-Tag" is a glutathione thiol transferase Tag, which has a relatively large molecular mass of about 26KD, and is inserted into the C-terminal or N-terminal of a target protein, commonly used in E.coli. GST (glutathione-sulfhydryl transferase) protein itself is a transferase that plays an important role in detoxification processes. The GST tag is generally selected for two purposes, namely, to improve the solubility of the protein expression and to improve the protein expression level. After the purification of the protein expression is finished, whether the tag is cut off or not is determined according to different protein applications, the tag is large, and whether the tag is cut off or not is considered according to downstream applications. If the GST fusion moiety is to be removed, it can be excised with a site-specific protease.
The term "MBP-Tag" is a maltose binding protein Tag, has the amino acid residue number of 346 and the molecular weight of 42.5kDa, is encoded by the malE gene of Escherichia coli K12, and can be placed at the N-terminal during construction to improve the solubility (especially eukaryotic proteins). Folding of MBP requires the assistance of two chaperone systems, dnaK-DnaJ-GrpE and GroEL-GeoES, which can bring these chaperones into the vicinity of the protein of interest to assist in its correct folding. In addition, the maltose binding protein in the form of the tag protein can reduce the degradation of the target protein, improve the water solubility of the expression product and provide a basis for the purification of the target protein in the future. The maltose binding protein can be adsorbed by the polysaccharide resin, so that the fusion protein can be separated from other protein components when passing through the column.
The term "NusA-Tag" is a transcription termination/anti-termination protein Tag, nusA is a protein of E.coli itself, namely transcription anti-termination factor, amino acid residue number 495, molecular weight: 54.87kDa, from 4000 E.coli protein libraries, davia, 1999. NusA does not have a separate purification tag function and is therefore used in combination with other tags (e.g. His tag).
The term "FLAG-Tag" is a fusion polypeptide of 8 amino acids (DYKDDDDK, SEQ ID No. 12), and the Kozak sequence constructed in the vector makes the expression of the FLAG-bearing fusion protein more efficient in eukaryotic expression systems.
The term "SUMO" is SUMO tag protein, is a small molecule ubiquitin related modified protein, and is a type of large protein which exists in eukaryotes and is highly conserved and involved in protein ubiquitination related modification. Compared with GST, MBP or NusA, SUMO not only can be used as a fusion tag of recombinant protein expression, but also has the function of molecular chaperones, can promote correct folding of the protein, has tolerance to heat and protease, and is more beneficial to maintaining the stability of target protein.
The term "Avi-Tag" is a 15 amino acid short peptide with a single biotinylated lysine site, which, in complete contrast to known natural biotinylated sequences, can be added at the N-and C-terminus of the target protein. After fusion expression, it can be biotinylated by biotin ligase, and low-affinity monomeric avidin or avidin derivatives are selected for purification of the recombinant protein.
The term "Halo-Tag" is a genetically modified derivative of a dehalogenase that is effectively covalently bound to a variety of synthetic HaloTag ligands. This monomeric protein with a molecular weight of 33kDa can be fused to the N-or C-terminus of the recombinant protein and expressed in both prokaryotic and eukaryotic systems. HaloTag ligands are small molecule chemicals capable of covalently binding to HaloTag proteins in vitro or in vivo.
The term "SNAP-Tag" is obtained from the methyl transfer of human O6-methylguanine-DNA (O6-alkylguanine-DNA-alkyltransferase). SNAP-Tag can be covalently bound to a substrate with high specificity, either in vivo or in vitro, to label proteins with biotin or fluorescent groups (e.g., fluorescein and rhodamine). The active sulfhydryl site carried by SNAP accepts a side chain benzyl group carried by benzyl guanine, releasing guanine. This novel thioether bond covalently binds to the target protein carried by SNAP carrying the tag carried by the benzyl group. Benzyl guanine is stable under biochemical conditions and no other proteins will interact with this class of substances, so SNAP tag reactions are highly specific.
The term "c-Myc" tag protein is a small tag of 10 amino acids (EQKLISEEDL, SEQ ID No. 13) that can still recognize its corresponding antibody as an epitope expressed in a different protein framework. C-Myc tag has been successfully used in Western-blot hybridization techniques, immunoprecipitation and flow cytometry, and can be used to detect expression of recombinant proteins in target cells. Common vectors are pCMV-MYC, pcDNA3.1 (+) -MYC-hisA, pCMV-RFP-C-Myc, pCMV-Myc, etc.
The term "HA" tag protein, tag sequence YPYDVPDYA (SEQ ID No. 14), is derived from hemagglutinin surface antigen determinant of influenza virus, 9 amino acids, HAs little influence on the spatial structure of exogenous target protein, and is easy to construct into a tag protein fused to N-terminal or C-terminal. Anti-HA antibody detection and ELISA detection are commonly used.
The term "luciferase" is derived from luciferin in an organism, and is commonly known as firefly luciferase, renilla luciferase and Guassia luciferase.
Examples
EXAMPLE 1 construction of eVLP backbone plasmid
The eVLP backbone used in this example was HIV-1 SF2 p 55 Gag (GenBank accession No. K02007) protein (SEQ ID No. 1), the Gag protein alone has the ability to self-assemble into coated VLP particles.
First, recombinant plasmids R1221 and R1242 containing Gag-GFP encoding genes were constructed, respectively: the polynucleotides SEQ ID No.7 and 8 which code for the amino acid sequences shown in SEQ ID No.1 and 3 are synthesized by Shanghai bioengineering Co., ltd, and the restriction enzyme BamHI cleavage site and the Kozak sequence are added to the 5' end; a stop codon TAA and a restriction enzyme XhoI cleavage site are added to the 3' -end. The synthesized product was digested with BamHI and XhoI restriction enzymes, and then subjected to agarose gel electrophoresis, and the desired fragment was recovered by gel cutting. The target fragment was ligated with pcNDA3.1 (+) which was also digested with the restriction enzymes BamHI and XhoI, respectively, to construct recombinant eukaryotic expression vectors, i.e., recombinant plasmids R1221 and R1242. Then, respectively converting recombinant plasmids R1221 and R1242 into E.coli DH5 alpha, culturing at 37 ℃ for 16 hours, picking single colonies, extracting plasmids, carrying out agarose gel electrophoresis identification on the extracted plasmids after double enzyme digestion of restriction enzymes BamHI and XhoI, sequencing positive clones by Shanghai bioengineering limited company, selecting clones with correct sequencing, amplifying and extracting plasmids, carrying out aseptic filtration on the extracted plasmids, and preserving at-20 ℃ for later use.
EXAMPLE 2 construction of Claudin 18.2 recombinant expression plasmid
First, recombinant plasmids R1353 and R1303 containing Claudin 18.2-GFP encoding genes were constructed, respectively: the polynucleotides SEQ ID No.9 and 10 encoding the amino acid sequences shown in SEQ ID No.4 and 5 are synthesized by Shanghai bioengineering Co-Ltd, and a restriction enzyme BamHI cleavage site and a Kozak sequence are added to the 5' end; a stop codon TAA and a restriction enzyme XhoI cleavage site are added to the 3' -end. The synthesized product was digested with BamHI and XhoI restriction enzymes, and then subjected to agarose gel electrophoresis, and the desired fragment was recovered by gel cutting. The target fragment was ligated with pcNDA3.1 (+) which was also digested with restriction enzymes BamHI and XhoI, respectively, to construct recombinant eukaryotic expression vectors, i.e., recombinant plasmids R1353 and R1303. Then, respectively converting recombinant plasmids R1353 and R1303 into E.coli DH5 alpha, culturing at 37 ℃ for 16 hours, picking single colonies, extracting plasmids, carrying out agarose gel electrophoresis identification on the extracted plasmids after double enzyme digestion of restriction enzymes BamHI and XhoI, sequencing positive clones by Shanghai bioengineering limited company, selecting clones with correct sequencing, amplifying and extracting plasmids, carrying out aseptic filtration on the extracted plasmids, and preserving at-20 ℃ for later use.
EXAMPLE 3 blank HIV-1 Gag-eVLP and Claudin 18.2-eVLP expression in HEK293 cells
3.1 expression of blank HIV-1 Gag-eVLP in HEK293 cells
The constructed recombinant plasmid R1242 is transfected into HEK293 cells (corresponding to the cell ID of R1242) by using PEI transfection reagent, and blank control eVLP expression and assembly are carried out. HEK293 cells were passaged 1X 10≡6 cells/mL the day before transfection and cultured at 37 ℃. The number is counted on the day of transfection, the cell density is adjusted to be 2X 10-6 cells/mL, and the activity rate is more than 95%.
The amounts of each component in the transfection complex were calculated from the cell density: the corresponding relation between the plasmid dose and the number of cells is that 1X 10≡6 cells correspond to 0.6 mug plasmid, and the corresponding relation between the PEI dose and the plasmid dose is that: the mass of PEI is 3 times the mass of DNA.
The transfection complexes were configured according to the amounts of the components calculated above: 1.2mg of recombinant plasmid with the concentration of 200 mug/mL is added into CD 293TGE culture medium (Acrobiosystems; product number CM-1156-11) to 50mL (solution A), 3.6mg of PEI transfection reagent with the concentration of 1mg/mL is added into CD 293TGE culture medium to 50mL (solution B), after the mixture is uniformly mixed, solution B is slowly added into solution A, the mixture is uniformly mixed, and after standing for 10-15min at room temperature, the transfection mixture is slowly dripped into 1000mL HEK293 cells. 37 ℃,5% CO 2 After 48 hours of culture at 135rpm, the culture supernatant of R1242 was collected.
3.2 Expression of Claudin 18.2-eVLP in HEK293 cells
HEK293 cells (corresponding cell IDs RG288 (transfected with R1303 and R1221) and RG341 (transfected with R1353 and R1242)) are obtained by respectively transfecting the constructed recombinant plasmids with the PEI transfection reagent according to the ratio of R1303:R1221=2:1 and R1353:2, and the expression and the assembly of eVLPs are carried out. HEK293 cells were passaged 1X 10≡6 cells/mL the day before transfection and cultured at 37 ℃. The number is counted on the day of transfection, the cell density is adjusted to be 2X 10-6 cells/mL, and the activity rate is more than 95%.
The amounts of each component in the transfection complex were calculated from the cell density: the corresponding relation between the plasmid dose and the number of cells is that 1X 10≡6 cells correspond to 0.6 mug plasmid, and the corresponding relation between the PEI dose and the plasmid dose is that: the mass of PEI is 3 times the mass of DNA.
The transfection complexes were configured according to the amounts of the components calculated above: adding 1.2mg of recombinant plasmid with the concentration of 200 mug/mL into CD 293TGE culture medium to 50mL (solution A), adding 3.6mg of PEI transfection reagent with the concentration of 1mg/mL into CD 293TGE culture medium to 50mL (solution B), respectively uniformly mixing, slowly adding the solution B into the solution A, uniformly mixing, and standing at room temperature After 10-15min, the transfection mixture was slowly added dropwise to 1000mL HEK293 cells. 37 ℃,5% CO 2 Culture supernatants of RG288 and RG341 were collected after 48 hours of culture at 135rpm, respectively.
EXAMPLE 4 isolation and purification of blank eVLP and Claudin 18.2-eVLP
The supernatant of the harvested R1242, RG288 and RG341 cells was centrifuged at 2000rpm at 4℃for 20min to remove cell debris and filtered with a 0.22 μm filter, and the supernatant was subjected to sucrose density gradient centrifugation, and the supernatant was subjected to 30% sucrose density ultracentrifugation (2,6000 rpm/min at 4℃for 1.5 h) and the pellet was resuspended in PBS to give crude pure samples of R1242, RG288 and RG341eVLP, respectively. SDS-PAGE was performed with separate samples, and the results are shown in FIG. 2, wherein lane A is R1242 as a crude pure sample, lane B is RG288 as a crude pure sample, and lane C is RG341 as a crude pure sample. The target bands for Gag (about 55 kDa) and Gag-GFP (about 80 kDa) were clearly seen from the electrophoresis results, demonstrating that the supernatant could be ultracentrifuged with a 30% sucrose pad density to yield a large amount of VLPs. To remove residual nucleic acid, crude and pure samples of R1242, RG288 and RG341 were treated with Benzonase (ACROBiosystems) having an enzyme concentration of 200U/mL at room temperature for 1 hour, respectively. The samples after nucleic acid removal were used separatelyExplorer (TM) 100 low pressure liquid chromatography System (GE Healthcare) SEC experiments were performed with Sepharose 6FF resin loaded into XK 16/70 chromatography columns (GE Healthcare) with a final bed volume of 130mL. The void volume of the column was determined using Blue Dextran 2000 (HMW calibration kit, GE Healthcare). Prior to eVLP separation, the column was washed with 3 column volumes of degassed Milli-Q ultrapure water, column equilibrated with 1 column volume of PBS, pH 7.4 at a rate of 2mL/min (60 cm/h).
Crude pure samples of R1242, RG288 and RG341 obtained above were injected into the loading ring and eluted at constant speed using PBS (pH 7.4) at a flow rate of 2mL/min (60 cm/h). Absorbance was measured at 280nm and 260nm on line. During the whole chromatography, samples were collected using a Frac 950 sample collector (GE Healthcare) and sampled for SDS-PAGE electrophoresis analysis, as shown in fig. 3, where plot a is R1242, plot B is RG288, and plot C is RG341. From the electrophoresis results, it can be seen that after separation by the crude pure sample SEC, high purity samples (indicated by arrows) can be obtained. And recovering high-purity samples according to electrophoresis results, namely eVLP, wherein the sample IDs are respectively marked as R1242-210521F1, RG288-210503F1 and RG341-210521F1.
EXAMPLE 5 morphological detection of Virus-like particles
To further confirm that the method of example 4 successfully produced eVLPs, transmission electron microscopy morphological examination (assigned to Peking, boseki technologies Co., ltd.) was performed on R1242-210521F1, and the results are shown in FIG. 4. It can be seen that R1242-210521F1 appears under electron microscopy as a hollow sphere with a diameter of about 150 nm. The electron microscopy results macroscopically demonstrate that the method of example 4 can successfully produce eVLPs with HIV-1 Gag as the scaffold protein.
Example 6 Activity detection of Claudin 18.2-eVLP with antibody IMAB362
In this example, ELISA (enzyme-linked immunosorbent assay) was used to detect the binding activity of Claudin 18.2-eVLP of the present disclosure to its specific antibody IMAB362, thereby demonstrating that Claudin 18.2 four transmembrane proteins were successfully displayed on eVLP in the correct conformation. The method comprises the following specific steps:
1. coating: 96-well plates (Corning Corp., cat# 42592) were coated with either RG288-210503F1 or RG341-210521F1 at 0.5 μg/well (5 μg/ml,100 μl/well) overnight (or 16 h) at 4deg.C. The coating buffer used for diluting RG288-210503F1 or RG341-210521F1 was 15mM Na 2 CO 3 ,35mM NaHCO 3 ,7.7mM NaN 3 ,pH9.6。
2. Washing: wells were washed 4 times with 300. Mu.l of wash buffer (TBS, 0.05% Tween-20, pH 7.4) per well (note: thorough removal of wash buffer is critical). After washing, the residual solution was removed by suction and was ensured to be completely dried.
3. Closing: each well was blocked with 300. Mu.l of blocking buffer (TBS, 2%BSA,pH7.4) for 1.5h at 37 ℃.
4. Washing: and (5) repeating the step 2.
5. Adding a sample: mu.l 0.390625-50ng/mL IMAB362 antibody was added to each well and incubated for 1h at 37 ℃. Samples were diluted in advance with dilution buffer (TBS buffer, pH7.4, containing 0.5% BSA).
6. Washing: and (5) repeating the step 2.
7. Adding a detection antibody: to each well 100. Mu.l of anti-human IgG antibody (Jackson, cat. No. 109-035-098) was added and incubated at 37℃for 1h. The antibodies were diluted in advance with dilution buffer (TBS buffer containing 0.5% BSA, pH 7.4) at a ratio of 1:20000.
8. Washing: and (5) repeating the step 2.
9. Adding a substrate: 200 μl of substrate solution was added to each well and incubated at 37deg.C for 20min. And (5) light shielding. Substrate solution preparation: after 10ml of substrate solution (50 mM Na 2 HPO 4 ·12H 2 O,25mM citric acid, pH 5.5) was added 8. Mu.l 3%H 2 O 2 And 100 μl of 10mg/ml TMB (BBI Life sciences, cat# A600954).
10. Terminating the reaction: to each well was added 50 μl of 1M sulfuric acid.
11. Reading OD value: OD values were read at 450nm, then OD450-ODBlank was the final OD value. Wherein the ODBlank corresponding wells were the results of the determination in step 5 without addition of sample and with addition of only an equal volume of dilution buffer, as a blank.
ELISA detection results are shown in FIG. 5, wherein FIG. A shows ELISA detection results of RG288-210503F1 and IMAB362 binding; panel B shows ELISA detection results of RG341-210521F1 and IMAB362 binding. The EC50 values of Claudin 18.2-eVLP RG288-210503F1 and RG341-210521F1 binding to IMAB362 of the present disclosure were 1.64ng/mL and 1.94ng/mL, respectively, indicating that Claudin 18.2-eVLP of the present disclosure has good binding activity to IMAB362, thereby proving that Claudin 18.2 tetraspanins were successfully displayed on eVLP in the correct conformation.
Example 7 preparation of IMAB362 CAR-like (HEK 293) cells
In this example, IMAB362 CAR-like (HEK 293) cells were prepared to mimic CAR-T cells to verify the use of Claudin 18.2-eVLP in assessing CAR positive expression rates.
7.1 preparation of IMAB362 CAR-like recombinant plasmid
The IMAB362 CAR structure is shown in figure 6. The corresponding amino acid sequence is 6, and the polynucleotide sequence is SEQ ID No.11. Plasmid construction methods refer to example 1.
7.2 preparation of IMAB362 CAR-like (HEK 293) cells
Procedure of IMAB362 CAR recombinant plasmid transfection HEK293 cells is referred to in example 3. Except that in this example IMAB362 CAR-like (HEK 293) monoclonal cells, labeled with ID C633, were required to be screened for resistance to G418 for CAR positive expression rate assessment experiments.
Example 8 Claudin-18.2-eVLP for CAR positive expression Rate assessment
In this example, anti-Fab antibodies FITC-anti-mFab Ab (Thermo Scientific, cat. No. 31543)), FITC-Protein L (ACROBiosystems, cat.No.RPL-PF 141), claudin 18.2 extracellular loop domain Protein were used, respectively: claudin-18.2 Protein,His Tag TM (ACROBiosystems, cat.No.CL2-H51H 6) R1242-210521F1, RG288-210503F1 and RG341-210521F1 of the present disclosure evaluate IMAB362 CAR expression. The method comprises the following specific steps:
1. Culturing C633 cells in DMEM medium containing 10% foetal calf serum, and placing in CO 2 In an incubator (37 ℃,5% CO) 2 )。
2. Cells were collected and washed once with FACS buffer (2% bsa).
3. The number and viability of cells were counted and 2X 10-6 viable cells were placed into each tube.
4. FITC-anti-mFab Ab, FITC-Protein L, claudin-18.2 Protein,His Tag TM The samples R1242-210521F1, RG288-210503F1 and RG341-210521F1 were each serially diluted with FACS buffer (2% BSA) and the diluted sample solutions were then added to the tubes containing the cells, respectively. Mixing well, and incubating at 4 ℃ for 60min. (for Claudin-18.2 Protein,His Tag TM After incubation, cells were washed 1 time with FACS buffer (2% BSA), PE-anti His antibody (Biolegend, cat. No. 362603) was added and incubated at 4℃for 60min in the dark. )
5. Cells were washed 3 times with FACS buffer (2% bsa) and finally cell samples were resuspended with 0.2ml pbs.
6. The cell suspension was transferred to a flow tube and detected by flow cytometry (excitation wavelength 488nm, emission wavelength 530 nm).
7. The resulting data was analyzed using FCS Express 6Plus and GraphPad Prism 5 software.
The results are shown in figure 7, where panel a is the assessment of IMAB362 CAR-like expression (positive rate 95.93%) when FITC-anti mFab was diluted 200-fold; panel B is an evaluation of IMAB362 CAR-like expression (positive rate 64.70%) when FITC-Protein L was used at a concentration of 10 μg/mL; panel C is when Claudin-18.2 Protein,His Tag TM When the concentration is 10 mug/mL, the expression condition of the IMAB362 CAR-like is evaluated (the positive rate is 1.17%), which indicates that only the extracellular loop region of Claudin18.2 is expressed and the IMAB362 CAR-like structure cannot be identified; panel D is an evaluation of IMAB362 CAR-like expression (99.52% positive rate) when RG288-210503F1 was used at a concentration of 10 μg/mL; panel E is an evaluation of IMAB362 CAR-like expression (positive rate 99.60%) when RG341-210521F1 was used at a concentration of 10. Mu.g/mL (R1242-210521F 1 is blank eVLP).
From the results, it can be seen that claudin18.2 target antigen displayed on claudin 18.2-eklp of the present disclosure is in correct conformation, can specifically bind to IMAB362 CAR-like, and shows the best effect when the positive expression rate of CAR is detected by FACS detection of GFP. The results indicate that Claudin 18.2-eklp containing green fluorescent protein GFP of the present disclosure is well suited for assessing CAR positive expression rates.
Example 9 CD20-eVLP for CAR positive expression rate assessment
In order to verify that the technical scheme of the disclosure can be applied to preparation of other multi-transmembrane proteins, and further applied to expression evaluation of CAR positive rates of other targeted multi-transmembrane proteins, the embodiment adopts the nano-particles of the disclosure to evaluate the CAR positive expression rates aiming at another multi-transmembrane protein CD 20. The method comprises the following specific steps:
1. Preparation of human CD 20-eVLP: constructing a recombinant plasmid containing a CD20 coding gene according to the method of the embodiment 2, wherein the amino acid sequence of the CD20 is shown as SEQ ID No.15, and the coding sequence of the CD20 is shown as SEQ ID No. 16; according to the method of example 3, a recombinant plasmid containing the CD20 encoding gene was combined with R1424 plasmid 2:1, mixing transfected HEK293 cells and collecting culture supernatant; the CD20-eVLP sample ID obtained by separation and purification according to the method of example 4 is RG344-210628F1;
2. preparation of Ofatumumab CAR-like (HEK 293) cells, preparation method was as described in example 7; wherein the amino acid sequence of the Ofatumumab CAR is SEQ ID No.17, and the polynucleotide sequence is SEQ ID No.18; the prepared Ofatumumab CAR-like (HEK 293) monoclonal cell is marked with an ID of RC539b and is used for a CAR positive expression rate evaluation experiment;
3. CD20-eVLP was used for CAR positive expression rate evaluation verification, specific methods refer to example 8.
The results are shown in FIG. 8, which evaluates the Ofatumumab CAR-like (HEK 293) expression (positive rate 99.48%) when RG344-210628F1 is used at a concentration of 20. Mu.g/mL (R1242-210521F 1 is blank eVLP).
From the results, it can be seen that the CD20 target antigen displayed on CD 20-eklp of the present disclosure is conformationally correct, can specifically bind to Ofatumumab CAR-like cell clones, and exhibits a positive rate effect of >99% when the positive expression rate of CAR is detected by FACS detection of GFP. The results further indicate that the technical means of the present disclosure can be widely applied to the preparation of multiple transmembrane protein-eVLPs, and further applied to the expression evaluation of CAR positive rates.
Claims (10)
- A nanoparticle, comprising:(i) An enveloped virus-like particle (eVLP) scaffold protein and/or a functional fragment thereof; and(ii) A target protein and/or a functional fragment thereof,wherein the enveloped virus-like particle framework protein comprises a virus core protein or a functional fragment thereof, the enveloped virus-like particle framework protein or the functional fragment thereof is assembled to form enveloped virus-like particles, and the target protein and/or the functional fragment thereof is displayed on the enveloped virus-like particles to form target protein-eVLP nanoparticles;preferably, the target protein is a CAR target protein; the CAR target protein and/or functional fragment thereof is displayed on an enveloped virus-like particle to form a CAR target protein-ehlp nanoparticle.
- The nanoparticle of claim 1, wherein the viral core protein is selected from the group consisting of: retrovirus Gag protein, baculovirus matrix protein M protein, filovirus core protein, coronavirus M, E and NP proteins, influenza virus M1 protein, paramyxovirus M protein, respiratory Syncytial Virus (RSV) M protein, arenavirus Z protein, newcastle disease virus M protein, parainfluenza virus M protein, bunyavirus N protein, hepatitis C virus core protein C, hepatitis b virus core protein C and combinations thereof;Preferably, the retroviral Gag protein is selected from: human immunodeficiency virus Gag protein, monkey immunodeficiency virus Gag protein, mouse leukemia virus Gag protein and bovine leukemia virus Gag protein; more preferably, the human immunodeficiency virus Gag protein comprises an amino acid sequence having at least 80% or more identity to SEQ ID No.1, preferably an amino acid sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably an amino acid sequence having 98% or more identity: more preferably, the amino acid sequence of the human immunodeficiency virus Gag protein is shown as SEQ ID No. 1;preferably, the baculovirus matrix protein M protein is vesicular stomatitis virus M virus core protein;preferably, the filovirus core protein is ebola virus VP40 virus core protein;preferably, the coronavirus core protein is selected from the group consisting of the core proteins of novel coronapneumoviruses (SARS-CoV-2), SARS-CoV, MERS-CoV, 229E, NL63, OC43 and HKU 1.
- The nanoparticle of claim 1 or 2, wherein the CAR target protein is a membrane protein,preferably, the membrane protein comprises a transmembrane protein; more preferably, the transmembrane protein comprises a plurality of transmembrane proteins;Preferably, the method comprises the steps of, the CAR target protein is selected from the group consisting of CD20, claudin18.1, claudin18.2, CD133, GPRC5D, CCR, CCR8, BCMA, GPCR, CD147, CD19, CD123, CD138, CD22, CD30, CD33, CD38, CD70, CAIX, EGFR, EGFRVIII, FOLR1, GPC3, HER2, HGFR, anti-FMC63 Ab, CLL-1, SLAMF7, CD4, CD5, CD8A & CD8B, FAP, IL13RA2, GPC3, GUCY2C, her3, PSMA, ROR1, SLAMF7, B7-H3, CD147, CEA, MUC16, nectin-4, VEGFR2, anti-RTX Ab, B7-H3, CAIX, CD7, CEA, MUC1 any of NKG2D, PSCA, uPAR, GD2, FR, PMEL, CA9, CD171/L1-CAM, IL-13Rα2, MART-1, ERBB2, ERBB3, ERBB4, NY-ESO-1, MAGE family protein, BAGE family protein, GAGE family protein, AFP, CD44v7/8, IL-11Rα, EGP-2, EGP-40, FBP, GD3, FSA, PSA, HMGA2, fetal acetylcholine receptor, leY, epCAM, mesothelin, IGFR1, CA125, CA15-3, CA19-9, CA72-4, CA242, CA50, CYFRA21-1, SCC, AFU, EBV-VCA, POA, β2-MG, PROGRP or MSLN;preferably, the CAR target protein is selected from any one of CD20, claudin18.2, CD133, GPRC5D, CCR, CCR8, CD19, BCMA, GPC3, CD30, CD22, EGFR, EGFRVIII, HER2, or GPCR;More preferably, the CAR target protein is claudin18.2; preferably, the amino acid sequence of claudin18.2 comprises an amino acid sequence having at least 80% or more identity to SEQ ID No.4, preferably an amino acid sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably an amino acid sequence having 98% or 99% or more identity: more preferably, the amino acid sequence of Claudin18.2 is shown as SEQ ID No. 4;more preferably, the CAR target protein is CD20; preferably, the amino acid sequence of CD20 comprises an amino acid sequence having at least 80% or more identity to SEQ ID No.15, preferably an amino acid sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably an amino acid sequence having 98% or more identity to SEQ ID No. 15: more preferably, the amino acid sequence of Claudin18.2 is shown as SEQ ID No. 15.
- A nanoparticle according to any one of claims 1 to 3, wherein the CAR target protein and/or functional fragment thereof and/or the viral core protein and/or functional fragment thereof is linked to a label;preferably, the N-terminus and/or C-terminus of the CAR target protein and/or functional fragment thereof and/or the N-terminus and/or C-terminus of the viral core protein and/or functional fragment thereof are linked to a tag; more preferably, the C-terminus of Claudin18.2 or the C-terminus of Gag is labeled with a label; more preferably, the C-terminal end of CD20 or the C-terminal end of Gag is labeled with a label;Preferably, the label is selected from the group consisting of a detectable label, a purification label, a reporter label, and combinations thereof;preferably, the detectable label is selected from the group consisting of a fluorescent group, a chemiluminescent label, an electrochemiluminescent label, and combinations thereof;preferably, the fluorophore is selected from any one of FITC, GFP, RFP, YFP, TRITC, PE, FAM, RRX, TR, cy, cy3, cy5, ECD, PC5.5, PC7, APC-A70, APC-A75, pac-Blue, alexa488, mBBr, 5-IAF, E-118, DTAF, rhodamine Green, and KrO;preferably, the chemiluminescent label is acridinium ester, isoluminol, horseradish peroxidase or alkaline phosphatase;preferably, the electrochemiluminescence label is ruthenium terpyridyl or a derivative N-hydroxysuccinimide ester thereof;preferably, the purification Tag is selected from any one of HIS-Tag, GST-Tag, MBP-Tag, nusA-Tag, FLAG-Tag, SUMO, avi-Tag, halo-Tag and SNAP-Tag;preferably, the purification tag is detected by a secondary antibody;preferably, the reporter tag is selected from any one of c-Myc, HA or luciferase.
- The nanoparticle of any one of claims 1-4, wherein the CAR target protein-vlp nanoparticle is selected from a Claudin 18.2-vlp nanoparticle or a CD 20-vlp nanoparticle;Preferably, said Claudin 18.2 and/or a functional fragment thereof and/or said viral core protein and/or a functional fragment thereof is linked to a marker;preferably, said CD20 and/or a functional fragment thereof and/or said viral core protein and/or a functional fragment thereof is linked to a label;preferably, the N-terminus and/or C-terminus of the Claudin 18.2 and/or functional fragment thereof and/or the N-terminus and/or C-terminus of the viral core protein and/or functional fragment thereof are linked to a tag;preferably, the N-terminus and/or C-terminus of the CD20 and/or functional fragment thereof and/or the N-terminus and/or C-terminus of the viral core protein and/or functional fragment thereof are linked to a label;preferably, the enveloped virus-like particle scaffold protein is Gag protein;preferably, the C-terminus of said Claudin 18.2 or the C-terminus of said Gag protein is linked to a marker;preferably, the C-terminus of the CD20 or the C-terminus of the Gag protein is linked to a label;preferably, the marker is GPF;preferably, the amino acid sequence of GFP comprises an amino acid sequence having at least 80% or more identity to SEQ ID No.2, preferably an amino acid sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably an amino acid sequence having 98% or more identity: more preferably, the amino acid sequence of GFP is shown as SEQ ID No. 2;Preferably, the C-terminal end of the Gag protein is linked to a marker GFP (Gag-GFP) whose amino acid sequence comprises an amino acid sequence having at least 80% or more identity to SEQ ID No.3, preferably an amino acid sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably an amino acid sequence having 98% or 99% or more identity: more preferably, the amino acid sequence of Gag-GFP is shown as SEQ ID No. 3;preferably, the C-terminal end of said Claudin 18.2 is linked to a marker GFP (Claudin 18.2-GFP) having an amino acid sequence with at least 80% or more identity to SEQ ID No.5, preferably an amino acid sequence with more than 85%, 90%, 95%, 96%, 97%, 98%, 99% identity, more preferably an amino acid sequence with more than 98% or 99% identity: more preferably, the amino acid sequence of Claudin 18.2-GFP is shown in SEQ ID No. 5.
- A method of preparing the nanoparticle of any one of claims 1-5, comprising:(1) Construction of recombinant plasmids:respectively constructing a recombinant plasmid containing envelope virus-like particle (eVLP) skeleton proteins and/or functional fragment genes thereof and a recombinant plasmid containing target proteins and/or functional fragment genes thereof; or constructing a recombinant plasmid simultaneously comprising an envelope virus-like particle (eVLP) framework protein and/or a functional fragment gene thereof and a target protein and/or a functional fragment gene thereof; and(2) Cell transfection, protein expression and particle assembly:transfecting the recombinant plasmid of the skeleton protein and/or the functional fragment thereof of the enveloped virus-like particle (eVLP) constructed in the step (1) and the recombinant plasmid of the target protein and/or the functional fragment thereof into cells, and expressing the skeleton protein and/or the functional fragment thereof of the enveloped virus-like particle and the target protein and/or the functional fragment thereof; the coated virus-like particle skeleton proteins or functional fragments thereof are assembled to form coated virus-like particles, and the target proteins and/or the functional fragments thereof are displayed on the coated virus-like particles to form target protein-eVLP nanoparticles; and, optionally,(3) Purifying target protein-eVLP nanoparticles;preferably, the coding nucleic acid sequence of the GAG comprises a nucleotide sequence having at least 80% or more identity to SEQ ID No.7, preferably a nucleotide sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably a nucleotide sequence having 98% or more identity to SEQ ID No. 7: more preferably, the amino acid sequence of GFP is shown as SEQ ID No. 7;preferably, the Gag-GFP encoding nucleic acid sequence comprises a nucleotide sequence having at least 80% or more identity to SEQ ID No.8, preferably a nucleotide sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably a nucleotide sequence having 98% or more identity to SEQ ID No. 8: more preferably, the amino acid sequence of GFP is shown as SEQ ID No. 8;Preferably, the coding nucleic acid sequence of Claudin 18.2 comprises a nucleotide sequence having at least 80% or more identity to SEQ ID No.9, preferably a nucleotide sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably a nucleotide sequence having 98% or 99% or more identity: more preferably, the amino acid sequence of GFP is shown as SEQ ID No. 9;preferably, the Claudin 18.2-GFP encoding nucleic acid sequence comprises a nucleotide sequence having at least 80% or more identity to SEQ ID No.10, preferably a nucleotide sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably a nucleotide sequence having 98% or 99% or more identity: more preferably, the amino acid sequence of GFP is shown as SEQ ID No. 10;preferably, the coding nucleic acid sequence of CD20 comprises a nucleotide sequence having at least 80% or more identity to SEQ ID No.16, preferably a nucleotide sequence having 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, more preferably a nucleotide sequence having 98% or more identity to SEQ ID No. 16: more preferably, the amino acid sequence of GFP is shown as SEQ ID No. 16.
- The method of claim 6, wherein the cell is selected from the group consisting of a prokaryotic host cell and a eukaryotic host cell;preferably, the prokaryotic host cell is any one of a bacterial cell, bacillus subtilis, and mycobacterium; preferably, the bacterial cell is escherichia coli;preferably, the eukaryotic host cell is selected from any one of an animal cell, a plant cell or a fungus;preferably, the eukaryotic host cell is selected from any one of yeast, insect, avian, plant, caenorhabditis elegans and mammalian host cells;preferably, the insect cell is selected from any one of Spodoptera frugiperda cells (e.g., sf9, sf 21), spodoptera frugiperda cells (e.g., high Five cells), and Drosophila S2 cells;preferably, the fungus is selected from any one of Saccharomyces cerevisiae, kluyveromyces lactis, candida species (e.g., candida albicans or candida glabrata), aspergillus nidulans, schizosaccharomyces pombe, pichia pastoris, and yarrowia lipolytica;preferably, the mammalian cells are selected from any one of COS cells, mouse L cells, LNCaP cells, chinese Hamster Ovary (CHO) cells, human Embryonic Kidney (HEK) cells (e.g., HEK293 cells), 633 cells, vero, BHK cells, african green monkey cells, CV1 cells, heLa cells, MDCK cells, and Hep-2 cells.
- A method of detecting a CAR positive expression rate, comprising: incubating the nanoparticle of any one of claims 1-5 or the nanoparticle prepared by the method of claim 6 or 7 with a CAR-modified cell, and then detecting; preferably, the cells are washed after incubation of the cells, prior to detection;preferably, the CAR-modified cell is selected from any one of a CAR-like (HEK 293) cell, a CAR-T cell, a CAR-NK cell, a CAR-M cell, a CAR-NKT cell, a CAR-Treg cell, and a CAR- γδ T cell;preferably, the temperature of the incubation is between 2 ℃ and 40 ℃, preferably 37 ℃, and/or the time of the incubation is between 15min and 2 hours, preferably 1 hour; and/or, the incubated CO 2 The concentration of (2) to 8%, preferably 5%;preferably, the number of washes is 1-6, preferably 3;preferably, the wash buffer is 0.5% -5% bsa, preferably 2% bsa;preferably, the detection is selected from any one of flow cytometry detection, immunodetection, ELISA, SPR, BLI.
- The method of claim 8, comprising incubating the Claudin 18.2-ehvlp nanoparticle or CD 20-ehvlp nanoparticle with a CAR-modified cell and then detecting;preferably, the enveloped virus-like particle scaffold protein is Gag protein;Preferably, the C-terminus of said Claudin 18.2 or the C-terminus of said Gag protein is linked to a marker;preferably, the C-terminus of the CD20 or the C-terminus of the Gag protein is linked to a label.
- A kit comprising the nanoparticle of any one of claims 1-5 or the nanoparticle prepared by the method of claim 6 or 7;preferably, the nanoparticle is a CAR target protein-ehlp nanoparticle;preferably, the kit comprises a labeled CAR target protein-ehlp nanoparticle;preferably, the kit comprises a labeled Claudin 18.2-ehlp nanoparticle;preferably, the kit comprises a labeled CD 20-ehlp nanoparticle;preferably, the kit is an ELISA kit, SPR kit or BLI kit;preferably, the ELISA kit comprises the CAR target protein-ekp, an ELISA plate, a blocking solution, a sample diluent, an enzyme conjugate, a concentrated wash solution, an enzyme substrate solution, and a stop solution;preferably, the SPR kit comprises the CAR target protein-ehlp nanoparticle;preferably, the BLI kit comprises the CAR target protein-ehlp nanoparticle.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110834195 | 2021-07-22 | ||
CN202110834195X | 2021-07-22 | ||
PCT/CN2022/107197 WO2023001256A1 (en) | 2021-07-22 | 2022-07-21 | Nanoparticle and use thereof in detection of car-positive expression rate |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116981684A true CN116981684A (en) | 2023-10-31 |
Family
ID=84979751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280020744.2A Pending CN116981684A (en) | 2021-07-22 | 2022-07-21 | Nanoparticle and application thereof in detection of CAR positive expression rate |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116981684A (en) |
WO (1) | WO2023001256A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117741162A (en) * | 2024-02-20 | 2024-03-22 | 苏州才博医学科技有限公司 | Cytology method for detecting donor specific antibody |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0426641D0 (en) * | 2004-12-03 | 2005-01-05 | Bioactive Protein Delivery The | Protein delivery system |
WO2015066715A1 (en) * | 2013-11-04 | 2015-05-07 | Viracell Advanced Products, Llc | Virus-like particles and methods related thereto |
-
2022
- 2022-07-21 CN CN202280020744.2A patent/CN116981684A/en active Pending
- 2022-07-21 WO PCT/CN2022/107197 patent/WO2023001256A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2023001256A1 (en) | 2023-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102488477B1 (en) | Cellular platform for rapid and comprehensive t-cell immunomonitoring | |
US10197562B2 (en) | Multiplex immuno screening assay | |
RU2740648C2 (en) | Constructed high-affinity human t-cell receptors | |
Tse Sum Bui et al. | Molecularly imprinted polymers as synthetic antibodies for protein recognition: the next generation | |
EP1187928A2 (en) | Virus like particles, preparation and use in screening and functional genomics | |
US20170145060A9 (en) | Means and methods for breaking noncovalent binding interactions between molecules | |
CN105473745B (en) | For characterizing the function of people's memebrane protein and the virion display array of interaction | |
AU2018366480C1 (en) | Novel mammalian expressed human immunodeficiency virus envelope protein antigens | |
Liu et al. | Membrane topology analysis of HIV-1 envelope glycoprotein gp41 | |
CN107223136B (en) | Method for introducing antibody into cell | |
JP5647599B2 (en) | Method for detecting a substance in a biological sample | |
CN116981684A (en) | Nanoparticle and application thereof in detection of CAR positive expression rate | |
EP2583974B1 (en) | Pseudotyping of foamy viruses | |
US20020052040A1 (en) | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics | |
EP1219705B1 (en) | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics | |
EP4196589A1 (en) | Fusion proteins comprising sars-cov-2 receptor binding domain | |
Argentinian AntiCovid Consortium et al. | Production of a highly immunogenic antigen from SARS-CoV-2 by covalent coupling of the receptor binding domain of spike protein to a multimeric carrier | |
US7476517B2 (en) | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics | |
WO2024071043A1 (en) | Production method of heteromultimeric protein, protein, nucleic acid, expression vector, transformant, and production method of protein | |
US20220042991A1 (en) | Viral Assay Method | |
WO2023018805A1 (en) | Methods and related aspects of detecting and purifying influenza neuraminidase | |
RU2509805C2 (en) | METHOD OF OBTAINING RECOMBINANT ANTIGEN G2 OF DOBRAVA HANTAVIRUS IN E.coli CELLS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |